Contacts

MedinCell announces fiscal year consolidated results April 2020 – March 2021

June 16, 2021

Income from ordinary activities: €11.8 million (+96% compared to the previous year)
Operating expenses: €27.1 million (+8%)
Cash consumption from operations: €12.1 million
Available cash: €47.1 million + €3.9 million of non-risky financial assets
Estimated financial visibility until summer 2023


Key developments of the product portfolio over the period April 2020-March 2021
• Following the announcement of positive results for the Phase 3 trial of mdc-IRM / TV46000 (schizophrenia) in January 2021, Teva Pharmaceuticals, which is leading and funding the program, is preparing for the U.S. regulatory filing, which is expected in mid-2021.
• Expected by the end of 2021, the findings of the ongoing analysis of the results of the first-in-human study of mdc-TJK, the second program in partnership with Teva Pharmaceuticals, will drive future developments.
• End of the Phase 2 clinical trial of mdc-CWM (post-operative pain and inflammation), developed with AIC. Our partner plans to launch new safety and efficacy clinical studies (Phase 3) in 2021.
• Selection of candidate formulations and entry into regulatory development of four new products: mdc-WWM (contraception), mdc-GRT (organ transplant), mdc-KPT (pain/animal health) and mdc-TTG (prophylaxis against Covid-19 and its variants).
• Post-closing: the company announced on June 15, 2021 the selection of a candidate formulation for the mdc-STM (malaria) program supported by the international health agency Unitaid, paving the way for the launch of pre-clinical activities.

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.